The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Relationships Between Bone Mineral Density and Incident Vertebral Fracture Risk with Raloxifene Therapy
Open accessAbstract
Although low absolute values of bone mineral density (BMD) predict increased fracture risk in osteoporosis, it is not certain how well increases in BMD with antiresorptive therapy predict observed reductions in fracture risk. This work examines the relationships between changes in BMD after 1 year or 3 years of raloxifene or placebo therapy and the risk for new vertebral fractures at 3 years. In the Multiple Outcomes of Raloxifene Evaluation (MORE) trial, 7705 postmenopausal women with osteoporosis were randomized to placebo or raloxifene 60 mg/day or 120 mg/day. Relationships between baseline BMD and changes in BMD from baseline with the risk of new vertebral fractures were analyzed in this cohort using logistic regression models with the raloxifene doses pooled. As has been observed in other populations, women with the lowest baseline lumbar spine or femoral neck BMD in the MORE cohort had the greatest risk for vertebral fractures. Furthermore, for any percentage change, either increase or decrease in femoral neck or lumbar spine BMD at 1 year or 3 years, raloxifene-treated patients had a statistically significantly lower vertebral fracture risk compared with placebo-treated patients. The decrease in fracture risk with raloxifene was similar across the range of percentage change in femoral neck BMD observed at 3 years; patients receiving raloxifene had a 36% lower risk of vertebral fracture compared with those receiving placebo. At any percentage change in femoral neck and lumbar spine BMD observed at 1 year, raloxifene treatment decreased the risks of new vertebral fractures at 3 years by 38% and 41%, respectively. The logistic regression model showed that the percentage changes in BMD with raloxifene treatment accounted for 4% of the observed vertebral fracture risk reduction, and the other 96% of the risk reduction remains unexplained. The present data show that the measured BMD changes observed with raloxifene therapy are poor predictors of vertebral fracture risk reduction with raloxifene therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McCullagh, P., & Nelder, J. A. (1989) · doi:10.1007/978-1-4899-3242-6 · Cited by 16,836
Marshall, D., Johnell, O., & Wedel, H. (1996) · BMJ · doi:10.1136/bmj.312.7041.1254 · Cited by 3,709
Bone density at various sites for prediction of hip fractures
Cummings, S. R., Browner, W., Cummings, S. R., Black, D. M., Nevitt, M. C., Browner, W., Genant, H. K., Cauley, J., Ensrud, K., Scott, J., et al. (1993) · The Lancet · doi:10.1016/0140-6736(93)92555-8 · Cited by 2,446
Self-citationRisk of New Vertebral Fracture in the Year Following a Fracture
Lindsay, R. (2001) · JAMA · doi:10.1001/jama.285.3.320 · Cited by 1,897
Surrogate End Points in Clinical Trials: Are We Being Misled?
Fleming, T. R., & DeMets, D. L. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-7-199610010-00011 · Cited by 1,651
Pre-Existing Fractures and Bone Mass Predict Vertebral Fracture Incidence in Women
Ross, P. D., Davis, J. W., Epstein, R. S., & Wasnich, R. D. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-11-919 · Cited by 1,107
Long-term fracture prediction by bone mineral assessed at different skeletal sites
Dr. Melton, L. J., Atkinson, E. J., O'Fallon, W. M., Wahner, H. W., & Riggs, B. L. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650081010 · Cited by 862
Black, D. M., Arden, N. K., Palermo, L., Pearson, J., Cummings, S. R., & for the Study of Osteoporotic Fractures Research Group (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.5.821 · Cited by 800
Self-citationInterim Report and Recommendations of the World Health Organization Task-Force for Osteoporosis
Genant, H. K., Cooper, C., Poor, G., Reid, I., Ehrlich, G., Kanis, J., Nordin, B. E. C., Barrett-Connor, E., Black, D., Bonjour, J.-P., et al. (1999) · Osteoporosis International · doi:10.1007/s001980050224 · Cited by 783
Self-citationKleerekoper, M., Villanueva, A. R., Stanciu, J., Rao, D. S., & Parfitt, A. M. (1985) · Calcified Tissue International · doi:10.1007/bf02554913 · Cited by 695
Statistical validation of intermediate endpoints for chronic diseases
Freedman, L. S., Graubard, B. I., & Schatzkin, A. (1992) · Statistics in Medicine · doi:10.1002/sim.4780110204 · Cited by 651
Treatment of Postmenopausal Osteoporosis
Eastell, R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803123381107 · Cited by 615
Legrand, E., Chappard, D., Pascaretti, C., Duquenne, M., Krebs, S., Rohmer, V., Basle, M.-F., & Audran, M. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.1.13 · Cited by 381
Relationship of Bone Turnover to Bone Density and Fractures
Melton, L. J., Khosla, S., Atkinson, E. J., O'Fallon, W. M., & Riggs, B. L. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.7.1083 · Cited by 350
Relationship between body composition and bone mass in women
Khosla, S., Atkinson, E. J., Riggs, B. L., & Melton, L. J. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110618 · Cited by 341
Liu, G., Peacock, M., Eilam, O., Dorulla, G., Braunstein, E. M., & Johnston, C. C. (1997) · Osteoporosis International · doi:10.1007/bf02652563 · Cited by 307
Hochberg, M. C., Ross, P. D., Black, D., Cummings, S. R., Genant, H. K., Nevitt, M. C., Barrett-Connor, E., Musliner, T., Thompson, D., & for the Fracture Intervention Trial Research Group (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199906)42:6<1246::aid-anr22>3.0.co;2-u · Cited by 287
Self-citationCummings, S. R. (2000) · JAMA · doi:10.1001/jama.283.10.1318 · Cited by 249
Burger, H., van Daele, P. L. A., Algra, D., van den Ouweland, F. A., Grobbee, D. E., Hofman, A., van Kuijk, C., Schütte, H. E., Birkenhäger, J. C., & Pols, H. A. P. (1994) · Bone and Mineral · doi:10.1016/s0169-6009(08)80203-6 · Cited by 198
Riggs, B. L., Melton, L. J., & O'Fallon, W. M. (1996) · Bone · doi:10.1016/8756-3282(95)00502-1 · Cited by 183
Body weight versus body fat distribution, adiposity, and frame size as predictors of bone density
Glauber, H. S., Vollmer, W. M., Nevitt, M. C., Ensrud, K. E., & ORWOLL, E. S. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.4.7714079 · Cited by 144
Long-Term Precision of DXA Scanning Assessed over Seven Years in Forty Postmenopausal Women
Patel, R., Blake, G. M., RYMER, J. M., & Fogelman, I. (2000) · Osteoporosis International · doi:10.1007/s001980050008 · Cited by 115
Lü, Y., Mathur, A. K., Blunt, B. A., Glüer, C., Will, A. S., Fuerst, T. P., Jergas, M. D., Andriano, K. N., Cummings, S. R., & Genant, H. K. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110510 · Cited by 100
Haddaway, M. J., Davie, M. W. J., & McCall, I. W. (1992) · British Journal of Radiology · doi:10.1259/0007-1285-65-771-213 · Cited by 63
Comparative calibration without a gold standard
Lü, Y., Keying Ye, B., Mathur, A. K., Hui, S. L., Fuerst, T. P., & Genant, H. K. (1997) · Statistics in Medicine · Cited by 56
The effect of modelling and remodelling on human vertebral body architecture
Mosekilde, L. (1998) · Technology and Health Care · doi:10.3233/thc-1998-65-602 · Cited by 53
Secondary osteoporosis and the risk of vertebral deformities in women
Melton, L. J., Atkinson, E. J., Khosla, S., O’Fallon, W. M., & Riggs, B. L. (1999) · Bone · doi:10.1016/s8756-3282(98)00150-1 · Cited by 46
The Role of Selective Estrogen Receptor Modulators in the Prevention and Treatment of Osteoporosis
Lufkin, E. G., Wong, M., & Deal, C. L. (2001) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70192-7 · Cited by 34
Self-citation
Cited by
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
Kanis, J. A., McCloskey, E. V., Johansson, H., Cooper, C., Rizzoli, R., Reginster, J.-Y., & on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) · Osteoporosis International · doi:10.1007/s00198-012-2074-y · Cited by 2,948
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF), Kanis, J. A., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2019) · Osteoporosis International · doi:10.1007/s00198-018-4704-5 · Cited by 1,900
“For raloxifene, the percentage changes in BMD accounted for 4% of the observed vertebral fracture risk reduction [341].”
BackgroundEpidemiology, etiology, and diagnosis of osteoporosis
Lane, N. E. (2006) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.08.047 · Cited by 1,293
for the IOF-IFCC Bone Marker Standards Working Group, Vasikaran, S., Eastell, R., Bruyère, O., Foldes, A. J., Garnero, P., Griesmacher, A., McClung, M., Morris, H. A., Silverman, S., et al. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1501-1 · Cited by 1,212
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
Kanis, J. A., Burlet, N., Cooper, C., Delmas, P. D., Reginster, J.-Y., Borgstrom, F., Rizzoli, R., & on behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) (2008) · Osteoporosis International · doi:10.1007/s00198-008-0560-z · Cited by 776
Metadata
- Authors
- Sarkar, S., Mitlak, B. H., Wong, M., Stock, J. L., Black, D. M., & Harper, K. D.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-01-01
- Volume
- 17
- Issue
- 1
- Pages
- 1-10
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W1985160737
- Cited by
- 442
- References
- 30
- FWCI
- 42.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.